Rocklatan (latanoprost/netarsudil) / Alcon - LARVOL DELTA

GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=426 | Completed | Sponsor: Alcon Research | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Rocklatan Retinal Perfusion OCT Study (clinicaltrials.gov) - P4 | N=30 | Not yet recruiting | Sponsor: Oregon Health and Science University

New P4 trial • Glaucoma • Ophthalmology

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=470 | Recruiting | Sponsor: Alcon Research | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=426 | Active, not recruiting | Sponsor: Alcon Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

Intraocular Pressure Equations Utilizing Aqueous Fluid Flow and Flow Facility in the Steady-State and Time-Dependent Domains. (PubMed, Clin Ophthalmol) - "The steady-state equation was validated by replicating the results of a published IOP efficacy study of combined netarsudil and latanoprost treatment results with a 3% error. Enhanced IOP equations provide a novel framework for modeling IOP dynamics. Potential applications include understanding IOP pathophysiology, evaluating therapeutic interventions, and predicting temporal/diurnal IOP fluctuations."

Journal • Cardiovascular • CNS Disorders • Glaucoma • Ophthalmology

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=470 | Not yet recruiting | Sponsor: Alcon Research

New P3 trial • Cardiovascular • Glaucoma • Ophthalmology

D-optimal candexch algorithm-enhanced machine learning UV-spectrophotometry for five-analyte determination in novel anti-glaucoma formulations and ocular fluids: four-color sustainability framework with NQS assessment and UN-SDG integration. (PubMed, BMC Chem) - "The novel anti-glaucoma ophthalmic preparation containing latanoprost, netarsudil, and benzalkonium chloride has posed a significant challenge due to its complexity and the lack of environmentally sustainable quantification methods, with only a single published method available for its quantification that lacks environmental consideration...Additionally, the method's environmental and societal benefits were further validated using the Need, Quality, Sustainability (NQS) index. Overall, this machine learning-based framework contributes meaningfully to ten United Nations Sustainable Development Goals (UN-SDGs), underscoring its value for future-oriented pharmaceutical research."

Journal • Glaucoma • Ophthalmology

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) (clinicaltrials.gov) - P4 | N=68 | Not yet recruiting | Sponsor: Center for Sight Las Vegas

New P4 trial • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: Prairie Eye Center | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Not yet recruiting | Sponsor: Prairie Eye Center

New P4 trial • Glaucoma • Ophthalmology

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment (clinicaltrials.gov) - P=N/A | N=70 | Recruiting | Sponsor: Colorado Ophthalmology Associates PC | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: Colorado Ophthalmology Associates PC

New trial • Glaucoma • Ophthalmology

netarsudil plus latanoprost (Roclanda) is accepted for restricted use within NHSScotland (Scottish Medicines Consortium) - "Indication under review: for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. SMC restriction: for use in patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if: the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or a fixed-dose combination treatment containing beta-blockers is unsuitable."

Reimbursement • Glaucoma • Ophthalmology

Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study. (PubMed, Clin Ophthalmol) - "In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients."

Clinical • Journal • P4 data • Cardiovascular • Glaucoma • Ophthalmology

GLR305-E001: Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=450 | Recruiting | Sponsor: Alcon Research | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Next Generation Rocklatan (clinicaltrials.gov) - P2 | N=450 | Not yet recruiting | Sponsor: Alcon Research

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology

Rocklatan Could Raise Hopes For Glaucoma Patients. (ESCRS 2023) - "ROCKLATAN with once-daily dosing, has shown to be more effective than using either netarsudil or latanoprost alone. This combination has the potential to decrease the treatment burden and improve adherence and clinical outcomes for patients with open-angle glaucoma or ocular hypertension."

Clinical • Glaucoma • Ophthalmology

Mercury-3 Exploratory Analyses: Netarsudil/Latanoprost Efficacy And Tolerability Stratified By Prior Prostaglandin Use In Patients With Glaucoma And Ocular Hypertension. (ESCRS 2023) - "The exploratory analysis of MERCURY-3 demonstrated that the IOP-reducing efficacy of NET/LAT was consistent whether a patient had received prior PGA (either as monotherapy or in combination) or not. The corresponding hyperaemia frequency figures for patients with/without prior PGA therapy were similar in the NET/LAT and BIM/TIM arms. These findings can help physicians to make informed decisions on treatment initiation for optimized management of glaucoma and ocular hypertension."

Clinical • Glaucoma • Ophthalmology

MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye. (PubMed, J Cataract Refract Surg) - "The addition of acetazolamide lowered the pressure to 19 mm Hg in both eyes, but she tolerated it poorly...However, by postoperative week 3, IOP returned to 27 mm Hg, and despite restarting latanoprost-netarsudil and finishing her steroid taper, IOP remained at 27 mm Hg by postoperative week 6...Knowing her postoperative course in the left eye, how would you manage the right eye? In addition to currently available options, would you consider a supraciliary shunt such as the MINIject (iSTAR) if such a device were U.S. Food and Drug Administration (FDA)-approved?"

Journal • Cataract • Glaucoma • Ophthalmology

"rhopressa, rocklatan" (@YichengB)

Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey. (PubMed, J Curr Glaucoma Pract) - "While the Rho Kinase Elevated intraocular Pressure (IOP) Treatment (ROCKET) trials compared monotherapy with ROCK inhibitor netarsudil vs timolol, MERCURY trials compared a fixed dose combination of latanoprost and ROCK inhibitor netarsudil [fixed combination netarsudil-latanoprost (FCNL)] vs monotherapy with either and bimatoprost-timolol combination. Singh K, Singh A. Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey. J Curr Glaucoma Pract 2023;17(1):44-48."

Journal • Review • Colorectal Cancer • Diabetic Retinopathy • Gastrointestinal Cancer • Glaucoma • Oncology • Ophthalmology • Rectal Cancer • Retinal Disorders • Solid Tumor

Rocklatan® Evaluation (clinicaltrials.gov) - P4 | N=136 | Completed | Sponsor: Aerie Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Improved glaucoma medication access through pharmacy partnership to minimize out-of-pocket costs: A single institution experience (ARVO 2023) - "Of the 343 inquiries, 211 were for Rocklatan; initial responses were 125 covered, 81 not on formulary, and 8 requiring prior authorizations...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Licensing / partnership • Glaucoma • Ophthalmology